AI-discovered peptide BRP shows GLP-1-free appetite suppression in preclinical models

Stanford researchers publishing in Science Daily (April 12) unveiled AI-discovered peptide BRP, which reduced appetite and induced weight loss in animal models without nausea or muscle wasting—GLP-1's troublesome side effects. Parallel Genome Medicine research (March 29) identified ~10% of patients with GLP-1 resistance. The Ozempic/Wegovy market is entering precision medicine territory.